|
Myocardial Infarction
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
IL-1β-511C/T gene polymorphism may be related to the risk of MI complicated with IS.
|
30542472 |
2018 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
These randomized double-blind placebo-controlled data suggest that therapy with canakinumab, an interleukin-1β inhibitor, is related to a dose-dependent reduction in HHF and the composite of HHF or heart failure-related mortality in a population of patients with prior myocardial infarction and elevations in high-sensitivity C-reactive protein.
|
30586730 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accordingly, CANTOS trial using an interleukin-1 beta antibody confirmed that inflammatory cytokines contribute to the occurrence of myocardial infarction and cardiac death independent of changes in lipids.
|
30918936 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, a recent Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial revealed the efficacy of IL-1β inhibition in preventing recurrent cardiovascular events in patients with MI.
|
30930410 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cases had higher levels of IL-1Ra at all time-points leading up to first-time MI, and higher levels of IL-1Ra were associated with approximately 1.5-fold increased risk of MI, supporting the rationale to target IL-1 activation in order to reduce cardiovascular risk in PWH.
|
31077280 |
2020 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cardiac nerve sprouting after MI is associated in part with NF-κB activation in the PVN, and IL-1β is involved in the process.
|
31175933 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, these data highlight a key role for the IL-1R1/cardiac fibroblast signaling axis in regulating post-MI remodeling and provide support for the continued development of anti-IL-1 therapies for improving cardiac function after MI.
|
31393855 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, the CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) showed the successful anti-inflammatory benefit of canakinumab, a monoclonal antibody targeting interleukin-1ß (IL-1ß) toward major cardiovascular events (MACE) in patients with a previous myocardial infarction (MI).
|
31469975 |
2020 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
All in all, miR-132 inhibits cardiomyocyte apoptosis so as to ameliorate myocardial remodeling in rats with MI through IL-1β downregulation.
|
31621911 |
2020 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found that MI triggered NLRP3 inflammasome activation leading to conversion of interleukin-1β (IL-1β) and IL-18 into their active mature forms in the heart, which could expand the infarct size and drive cardiac dysfunction.
|
31645662 |
2020 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL-1β and Statin Treatment in Patients with Myocardial Infarction and Diabetic Cardiomyopathy.
|
31652822 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
We further evaluated the inflammation, fibrosis of left atria (LA), and related signal pathways by RT-PCR, Western blot, and staining analysis.Compared to the MI group, fisetin treatment improved cardiac function, inhibited macrophage recruitment into the LA and production of IL-1β and TNF-α, and attenuated adverse atrial fibrosis following acute myocardial infarction (AMI).
|
31666455 |
2019 |
|
Myocardial Infarction
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inflammasome activation and IL-1β secretion are implicated in myocardial infarction (MI) and resultant heart failure; however, little is known about how macrophage lysosomes regulate these processes.
|
31672943 |
2019 |